ASOFARMA Central America and the Caribbean is a leading pharmaceutical company in the region that develops, produces and markets innovative products in therapeutic areas such as oncology, cardiology, central nervous system, diabetes and urology, among others.

As part of the agreement, ASOFARMA will collaborate with Moderna in the management of supply contracts already in force, as well as in vaccine registration processes, support of pharmacovigilance activities, continuing medical education, governmental affairs, marketing, and generation of new agreements to facilitate the availability of SPIKEVAX in the region.

"We are delighted to partner with Moderna to help patients, physicians and governments in this effort against COVID-19. Moderna is a leader in the fight against the pandemic, and we are proud to have been chosen as a partner in this endeavor, providing all our experience and regional presence", said Bernardo Girala, General Manager of ASOFARMA Central America and the Caribbean.

"This alliance confirms our purpose of providing the population with innovative treatments that help improve their quality of life and expand vaccination rates in the region", said Girala.

Moderna Inc, a biotechnology company pioneer in the development of messenger ARN (ARNm), therapies and vaccines, has trusted ASOFARMA to make possible the arrival of its vaccine against COVID 19, Spikevax, in the region.

Moderna's (ARNm), platform is based on continuous advances in basic and applied mRNA science, delivery and manufacturing technology; which has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and autoimmune diseases.

With this new agreement reached by ASOFARMA, Moderna Inc. joins a list of international pharmaceutical and biotechnology research and development companies that ASOFARMA has been representing in the region for more than twenty years.